An influx of cheap, unlicensed weight-loss jabs could flood the UK black market as patents for Ozempic and Wegovy expire in several countries. Experts warn that knock-off versions may sell for as little as £10 a month, posing serious health risks.
The drugs, originally designed for Type 2 diabetes, have surged in popularity for weight loss. An estimated 1.6 million UK adults have used them in the past year, according to University College London. Novo Nordisk, the maker of semaglutide used in Wegovy and Ozempic, has lost patent protection in India and Canada, with further expirations in China, Brazil, and Turkey.
Following the Indian patent expiry on Friday, seven pharmaceutical firms announced plans to produce generic versions at much lower prices. Eris Life Sciences will sell a multi-dose vial for £10.33, while Glenmark offers a product costing between £10.39 and £14.08 per month. Zydus Lifesciences released reusable pens for £17.60.
Health officials voiced concerns at a Health and Social Care Committee meeting on Wednesday. Andy Morling of the Medicines and Healthcare Regulatory Agency reported that 81,000 unlicensed doses had been seized in the last three years. He noted that while many products are genuine, they may not meet UK manufacturing standards, with questionable sterility and dosage.
Dr Nadia Ahmad of The Weight Care Clinic warned: “People think they’re getting Ozempic or Wegovy but you don’t know what’s inside. Doses can be wrong, products can be contaminated, or completely fake.” She added that patients have suffered dehydration, electrolyte imbalance, pancreatitis, and in worst cases, fatal outcomes.
Experts advise obtaining these medications only through regulated pharmacies or services. Dr Suzanne Wylie, GP and medical adviser for IQDoctor, said: “These are powerful prescription drugs, and the risks of cutting corners to obtain them cheaply can far outweigh the benefits, particularly when you may be injecting something that hasn’t met basic safety standards.”
